GlaxoSmithKline Discontinues Flovent Rotadisk
This article was originally published in The Pink Sheet Daily
Executive Summary
The company cites manufacturing issues and low sales in deciding to discontinue the fluticasone dosage form. The asthma product will continue to be available as inhalation aerosol.
You may also be interested in...
GlaxoSmithKline Flovent HFA Clears FDA
The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.
AstraZeneca Joins The $35 Inhaler Club; Medicare Patients Waiting On Congress For Membership
AZ’s move follows Boehringer’s announcement earlier this month and parallels what insulin sponsors did – but almost in reverse. For inhalers, political pressure on out-of-pocket costs has produced copay caps in the commercial market first, not Medicare.